COPD
Investigational cell-based approaches to inflammatory burden, lung injury, functional decline, route of administration, and pulmonary safety.
Review the program →
Cell therapeutics & U.S. development strategy
Build cell-therapy programs on evidence, product control, and regulatory clarity.
Axiom supports research strategy, translational development, technical training, and practical quality readiness across cell-therapeutics programs—with focused work in COPD, systemic lupus erythematosus, and kidney injury.
3Focused disease areas
CMCProduct and process control
INDU.S. clinical pathway
GMPStage-appropriate quality
Research focus
Disease-led programs, not generic promises.
Each program starts with a defined product hypothesis, measurable biological activity, a risk-based evidence plan, and endpoints that matter for the target population.
Systemic lupus erythematosus
Modality-specific research for immune dysregulation, disease heterogeneity, flare control, organ involvement, and infection risk.
Review the program →Kidney injury
Translational research for acute and inflammatory kidney injury, emphasizing renal recovery, safety, biodistribution, and clinically meaningful endpoints.
Review the program →
Development capabilities
Connect the science to a reviewable U.S. development package.
A coherent program aligns the intended clinical use with manufacturing controls, potency, nonclinical evidence, clinical design, and regulatory interactions.
Product definition & CMC
Define source, composition, critical quality attributes, release strategy, comparability, stability, and the assays needed to control the product.
Nonclinical & translational plan
Link mechanism and potency to pharmacology, toxicology, biodistribution, persistence, thrombogenicity, and other modality-specific risks.
U.S. IND readiness
Organize the CMC, nonclinical, and clinical package; prepare for FDA interactions; and track questions, evidence gaps, and submission decisions.
Clinical development planning
Translate the product hypothesis into population, dose, route, monitoring, stopping rules, and endpoints without overstating expected benefit.
GMP & quality readiness
Build stage-appropriate facilities, procedures, training, documentation, qualification, deviation control, and supplier oversight.
Technical training
Develop hands-on, process-specific learning with documented competency goals for scientists, operators, and program leaders.
A critical distinction
Research, clinical authorization, and marketing approval are different milestones.
A ClinicalTrials.gov listing does not show that the U.S. government reviewed the science or found a therapy safe or effective. Filing an IND is not FDA approval. Even when an IND is in effect and a study may proceed, the product remains investigational.
Read the research & regulatory notice →